Gefitinib: A cause of pyogenic granulomalike lesions of the nail

Archives of Dermatology

Volumn 142, Issue 7, 2006, Pages 939-

  High, Whitney A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; INDINAVIR; PANITUMUMAB; RETINOID;

ACNE; ANAMNESIS; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DEBRIDEMENT; EYELASH; GRANULOMA; HUMAN; LOW LEVEL LASER THERAPY; LUNG NON SMALL CELL CANCER; NAIL DISEASE; NOTE; PARONYCHIA; PIGMENT DISORDER; PRIORITY JOURNAL; SIDE EFFECT; TELANGIECTASIA; XEROSIS;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; FEMALE; GRANULOMA, PYOGENIC; HUMANS; LUNG NEOPLASMS; NAIL DISEASES; QUINAZOLINES;

EID: 33746032248     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.7.939-a     Document Type: Note

References (5)

1. Frantz S. Drug discovery: playing dirty. Nature. 2005;437:942-943.
2. United States Food and Drug Administration. FDA Alert: Gefitinib (marketed as Iressa) Information. http://www.fda.gov/cder/drug/infopage/ gefitinib/default.htm. Accessed October 30, 2005.
3. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425-1433.
4. Lee MW, Seo CW, Kim SW, et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol. 2004;84:23-26.
5. Piguet V, Borradori L. Pyogenic granuloma-like lesions during capecitabine therapy. Br J Dermatol. 2002;147:1270-1272.